Pharmaceutical Suppositories Market By Type (Rectal Suppositories, Vaginal Suppositories, Urethral Suppositories), By Base (Fatty Bases, Water Miscible Base, Emulsifying Bases), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Sales), By End User (Hospitals and Clinics, Home Care, Nursing Home), By Prescription Type (OTC, Prescribed Suppositories): Global Opportunity Analysis and Industry Forecast, 2023-2032

Pharmaceutical Suppositories Market

The pharmaceutical suppositories market is likely to experience a significant growth rate of 5.7% from 2023-2032 owing to increasing market demand of rectal suppositories segment –

Pharmaceutical suppositories are solid, medicated dosage forms designed for rectal or vaginal administration. These small, often bullet-shaped units contain active pharmaceutical ingredients (APIs) dispersed in a suitable base material. When inserted into the body, they gradually melt or dissolve, allowing for the controlled release and absorption of the medication. Suppositories are used in medical practice to deliver localized treatment, bypass the first-pass metabolism in the liver, and offer an alternative when oral or intravenous routes are not ideal. They are employed in a wide range of medical conditions, including pain management, gastrointestinal issues, hormone therapy, and more, providing targeted drug delivery with minimized systemic effects.

The pharmaceutical suppositories market is experiencing significant growth driven by the growing prevalence of the geriatric population and the increasing incidence of acute and chronic diseases. As the world's population continues to age, there is a substantial rise in the number of elderly individuals who often require specialized medical treatments. Suppositories offer an effective and targeted drug delivery method, which is especially beneficial for older adults who may have difficulty swallowing or need localized treatment.

Moreover, the surge in acute and chronic diseases worldwide has bolstered the demand for suppositories. These dosage forms are crucial in managing various conditions such as constipation, pain, hemorrhoids, and inflammatory bowel diseases. For instance, according to the article published in Springer, in 2023, it states that average prevalence of constipation was estimated at 16% globally, while a prevalence of 33.5% was attributed to adults between 60 and 110 years old. This underscores the importance of suppositories in addressing healthcare needs, contributing to the growth of the pharmaceutical suppositories market as they provide effective solutions for patients of all ages.

Furthermore, the growing initiative taken by key players and the government organizations for awareness regarding use of suppositories are further driving the market growth. These initiatives are pivotal in market expansion by educating both healthcare professionals and the general public about the benefits and applications of suppository-based medications. By providing information and promoting the safe and effective use of suppositories, these stakeholders contribute to increased acceptance and utilization of this drug delivery method. Patients become more aware of the advantages of suppositories, while healthcare providers gain confidence in prescribing and administering them. This combined effort fosters a conducive environment for the pharmaceutical suppositories market to thrive, ultimately benefiting individuals who can benefit from these specialized and targeted treatment options.

The global pharmaceutical suppositories market is segmented based on type, base, distribution channel, end user, prescription type and region. On the basis of type, the market is divided into rectal suppositories, vaginal suppositories and urethral suppositories. On the basis of base, it is classified into fatty base, water miscible bases, and emulsifying bases. The water miscible bases are further segmented into glycero gelatin base, soap glycerin suppositories, and polyethylene glycol bases. The emulsifying bases are further segmented into witepsol, massa esterium, and massuppol. On the basis of distribution channel, the market is divided into hospital pharmacies, retail pharmacies and online sales. On the basis of end user, it is classified into hospitals & clinics, home care and nursing home. On the basis of prescription type, it is bifurcated into OTC and prescribed suppositories. On the basis of region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The report provides a comprehensive analysis of the key players that operate in the global pharmaceutical suppositories market such as Bayer AG, Bliss Gvs Pharma Ltd, Viatris Inc, Cadila Healthcare Ltd, Church & Dwight Co., Inc., Glenmark Pharmaceuticals Limited, Intas Pharmaceuticals Ltd., Novartis AG, Pfizer Inc., and Sanofi S.A. Key players operating in the market have adopted product approval as their key strategies to expand their product portfolio.

Key Market Insights (Updated)    

• On the basis of type, the rectal suppositories segment dominated the market in terms of revenue in 2022. However, the vaginal suppositories segment is anticipated to grow at the fastest CAGR during the forecast period.  

• On the basis of base, the emulsifying bases segment held largest market share in 2022 and is expected to remain dominant throughout the forecast period.  

• On the basis of distribution channel, the hospital pharmacies segment dominated the market in terms of revenue in 2022. However, the online sales segment is anticipated to grow at the fastest CAGR during the forecast period.  

• On the basis of end user, the hospitals & clinics segment dominated the market in terms of revenue in 2022. However, the home care segment is anticipated to grow at the fastest CAGR during the forecast period.   

• On the basis of prescription type, the prescribed suppositories segment held the largest market share in 2022. However, the OTC segment is anticipated to grow at the fastest CAGR during the forecast period.

• On the basis of region, North America generated the largest revenue in 2022. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period. 

 

Overview

The Pharmaceutical Suppositories Market was valued for $1,606.46 million in 2022 and is estimated to reach $2,802.05 million by 2032, exhibiting a CAGR of 5.7% from 2023 to 2032. 

Suppositories are solid dosage forms of medication that are precisely designed for insertion into bodily cavities other than the mouth. They can be placed in the rectum, vaginal canal, or urethra. These items are designed to melt or dissolve in the cavity fluids after insertion, allowing the drug to be released. On the basis of the site of insertion, suppositories are divided into rectal suppository, vaginal suppository, and urethral suppository. Suppositories have usefulness in on-site action. It omits the first-pass effect which save drug from metabolism. In case of bitter and obnoxious drugs, suppositories are used as drug delivering option. In pediatrics, suppositories are often used to treat symptoms similar to constipation. However, there is a possibility of mucosal irritation at the site of use which may limit its usage. 

The increase in prevalence of chronic diseases that necessitate the use of suppositories is a significant driver for the pharmaceutical suppositories market. Chronic conditions such as inflammatory bowel disease, hemorrhoids, and certain cancers often benefit from localized drug delivery, reducing systemic side effects. The demand for suppository-based treatments rises as these conditions become more common due to various factors such as lifestyle changes and aging populations. For instance, according to the article published in National Library of Medicine, stated that 320,000 people in Canada have been living with Inflammatory bowel disease (IBD), and the prevalence is forecasted to rise by 2.44% per year such 1.1% of the population, 470,000 Canadians, are anticipated to live with IBD by 2035. 

This trend offers substantial growth opportunities for pharmaceutical companies, leading to the development of new formulations and expanding the market for suppository-based medications to meet the healthcare needs of individuals with chronic diseases. 

However, limited drug compatibility hinders market growth as not all medications are effectively delivered through suppositories due to stability and solubility issues. In addition, manufacturing complexities, requiring specialized equipment and processes, increase production costs and restrict the number of manufacturers, limiting market accessibility and affordability. 

The pharmaceutical suppositories market is segmented into type, base, distribution channel, end user, prescription type and region. On the basis of type, the market is divided into rectal suppositories, vaginal suppositories and urethral suppositories. On the basis of base, it is classified into fatty base, water miscible bases, and emulsifying bases. The water miscible bases are further segmented into glycero gelatin base, soap glycerin suppositories, and polyethylene glycol bases. The emulsifying bases are further segmented into witepsol, massa esterium, and massuppol. 

On the basis of distribution channel, the market is divided into hospital pharmacies, retail pharmacies and online sales. On the basis of end user, it is classified into hospitals & clinics, home care and nursing home. On the basis of prescription type, it is bifurcated into OTC and prescribed suppositories. On the basis of region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. The major players that operate in the pharmaceutical suppositories market include Bayer AG, Bliss Gvs Pharma Ltd, Viatris Inc, Cadila Healthcare Ltd,  Church & Dwight Co., Inc., Glenmark Pharmaceuticals Limited, Intas Pharmaceuticals Ltd., Novartis AG, Pfizer Inc., and Sanofi S.A. 

suppositories provide great alternative of drug delivery and can be useful in case of unconscious patients or where direct on-site action is desired. 

The factors such as increased geriatric population, rise in number of gastro-intestinal diseases across the globe, rise in intra uterine diseases and various chronic diseases and rise in number of hospitals & clinics are expected to drive the growth of the pharmaceutical suppositories market. Moreover, the increase in use of rectal suppositories and technological advancements further boost the growth of the market. 

In addition, North America is expected to witness the highest growth, in terms of revenue, owing to ongoing technological advancements, a well-established and advanced healthcare infrastructure, and adoption of suppositories for treatment by patients and healthcare providers. However, Asia-Pacific is anticipated to witness notable growth, owing to a rise in geriatric population and an increase in initiative to expand the healthcare facilities in the region, thus driving the growth of the market during the forecast period.

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the pharmaceutical suppositories market analysis from 2022 to 2032 to identify the prevailing pharmaceutical suppositories market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the pharmaceutical suppositories market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global pharmaceutical suppositories market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

● Quarterly Update and* (only available with a corporate license, on listed price)

● 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.

● Free Upcoming Version on the Purchase of Five and Enterprise User License.

● 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)

● 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)

● Free data Pack on the Five and Enterprise User License. (Excel version of the report)

● Free Updated report if the report is 6-12 months old or older.

● 24-hour priority response*

● Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

● Regulatory Guidelines

● Additional company profiles with specific to client's interest

● Expanded list for Company Profiles

Key Market Segments

○ Glenmark Pharmaceuticals Limite

Scope of Pharmaceutical Suppositories Market Report

1.1. Report description

1.2. Key market segments

1.3. Key benefits to the stakeholders

1.4. Research methodology

1.4.1. Primary research

1.4.2. Secondary research

1.4.3. Analyst tools and models

2.1. CXO Perspective

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top impacting factors

3.2.2. Top investment pockets

3.3. Porter’s five forces analysis

3.3.1. High bargaining power of suppliers

3.3.2. Moderate threat of new entrants

3.3.3. Moderate threat of substitutes

3.3.4. Moderate intensity of rivalry

3.3.5. Moderate bargaining power of buyers

3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Rise in prevalence of acute & chronic disorders which require the use of suppository

3.4.1.2. Increase in the geriatric population

3.4.1.3. Increase in initiatives for awareness and education for use of suppositories

3.4.2. Restraints

3.4.2.1. Manufacturing complexities

3.4.2.2. Limited drug compatibility

3.4.3. Opportunities

3.4.3.1. Technological advancements in suppositories

4.1. Overview

4.1.1. Market size and forecast

4.2. Rectal Suppositories

4.2.1. Key market trends, growth factors and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market share analysis by country

4.3. Vaginal Suppositories

4.3.1. Key market trends, growth factors and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market share analysis by country

4.4. Urethral Suppositories

4.4.1. Key market trends, growth factors and opportunities

4.4.2. Market size and forecast, by region

4.4.3. Market share analysis by country

5.1. Overview

5.1.1. Market size and forecast

5.2. Fatty Bases

5.2.1. Key market trends, growth factors and opportunities

5.2.2. Market size and forecast, by region

5.2.3. Market share analysis by country

5.3. Water Miscible Base

5.3.1. Key market trends, growth factors and opportunities

5.3.2. Market size and forecast, by region

5.3.3. Market share analysis by country

5.3.4. Water Miscible Base Pharmaceutical Suppositories Market by Type

5.4. Emulsifying Bases

5.4.1. Key market trends, growth factors and opportunities

5.4.2. Market size and forecast, by region

5.4.3. Market share analysis by country

5.4.4. Emulsifying Bases Pharmaceutical Suppositories Market by Type

6.1. Overview

6.1.1. Market size and forecast

6.2. Hospital Pharmacies

6.2.1. Key market trends, growth factors and opportunities

6.2.2. Market size and forecast, by region

6.2.3. Market share analysis by country

6.3. Retail Pharmacies

6.3.1. Key market trends, growth factors and opportunities

6.3.2. Market size and forecast, by region

6.3.3. Market share analysis by country

6.4. Online Sales

6.4.1. Key market trends, growth factors and opportunities

6.4.2. Market size and forecast, by region

6.4.3. Market share analysis by country

7.1. Overview

7.1.1. Market size and forecast

7.2. Hospitals and Clinics

7.2.1. Key market trends, growth factors and opportunities

7.2.2. Market size and forecast, by region

7.2.3. Market share analysis by country

7.3. Home Care

7.3.1. Key market trends, growth factors and opportunities

7.3.2. Market size and forecast, by region

7.3.3. Market share analysis by country

7.4. Nursing Home

7.4.1. Key market trends, growth factors and opportunities

7.4.2. Market size and forecast, by region

7.4.3. Market share analysis by country

8.1. Overview

8.1.1. Market size and forecast

8.2. OTC

8.2.1. Key market trends, growth factors and opportunities

8.2.2. Market size and forecast, by region

8.2.3. Market share analysis by country

8.3. Prescribed Suppositories

8.3.1. Key market trends, growth factors and opportunities

8.3.2. Market size and forecast, by region

8.3.3. Market share analysis by country

9.1. Overview

9.1.1. Market size and forecast By Region

9.2. North America

9.2.1. Key market trends, growth factors and opportunities

9.2.2. Market size and forecast, by Type

9.2.3. Market size and forecast, by Base

9.2.4. Market size and forecast, by Distribution Channel

9.2.5. Market size and forecast, by End User

9.2.6. Market size and forecast, by Prescription Type

9.2.7. Market size and forecast, by country

9.2.7.1. U.S.

9.2.7.1.1. Market size and forecast, by Type

9.2.7.1.2. Market size and forecast, by Base

9.2.7.1.3. Market size and forecast, by Distribution Channel

9.2.7.1.4. Market size and forecast, by End User

9.2.7.1.5. Market size and forecast, by Prescription Type

9.2.7.2. Canada

9.2.7.2.1. Market size and forecast, by Type

9.2.7.2.2. Market size and forecast, by Base

9.2.7.2.3. Market size and forecast, by Distribution Channel

9.2.7.2.4. Market size and forecast, by End User

9.2.7.2.5. Market size and forecast, by Prescription Type

9.2.7.3. Mexico

9.2.7.3.1. Market size and forecast, by Type

9.2.7.3.2. Market size and forecast, by Base

9.2.7.3.3. Market size and forecast, by Distribution Channel

9.2.7.3.4. Market size and forecast, by End User

9.2.7.3.5. Market size and forecast, by Prescription Type

9.3. Europe

9.3.1. Key market trends, growth factors and opportunities

9.3.2. Market size and forecast, by Type

9.3.3. Market size and forecast, by Base

9.3.4. Market size and forecast, by Distribution Channel

9.3.5. Market size and forecast, by End User

9.3.6. Market size and forecast, by Prescription Type

9.3.7. Market size and forecast, by country

9.3.7.1. Germany

9.3.7.1.1. Market size and forecast, by Type

9.3.7.1.2. Market size and forecast, by Base

9.3.7.1.3. Market size and forecast, by Distribution Channel

9.3.7.1.4. Market size and forecast, by End User

9.3.7.1.5. Market size and forecast, by Prescription Type

9.3.7.2. France

9.3.7.2.1. Market size and forecast, by Type

9.3.7.2.2. Market size and forecast, by Base

9.3.7.2.3. Market size and forecast, by Distribution Channel

9.3.7.2.4. Market size and forecast, by End User

9.3.7.2.5. Market size and forecast, by Prescription Type

9.3.7.3. UK

9.3.7.3.1. Market size and forecast, by Type

9.3.7.3.2. Market size and forecast, by Base

9.3.7.3.3. Market size and forecast, by Distribution Channel

9.3.7.3.4. Market size and forecast, by End User

9.3.7.3.5. Market size and forecast, by Prescription Type

9.3.7.4. Italy

9.3.7.4.1. Market size and forecast, by Type

9.3.7.4.2. Market size and forecast, by Base

9.3.7.4.3. Market size and forecast, by Distribution Channel

9.3.7.4.4. Market size and forecast, by End User

9.3.7.4.5. Market size and forecast, by Prescription Type

9.3.7.5. Spain

9.3.7.5.1. Market size and forecast, by Type

9.3.7.5.2. Market size and forecast, by Base

9.3.7.5.3. Market size and forecast, by Distribution Channel

9.3.7.5.4. Market size and forecast, by End User

9.3.7.5.5. Market size and forecast, by Prescription Type

9.3.7.6. Rest of Europe

9.3.7.6.1. Market size and forecast, by Type

9.3.7.6.2. Market size and forecast, by Base

9.3.7.6.3. Market size and forecast, by Distribution Channel

9.3.7.6.4. Market size and forecast, by End User

9.3.7.6.5. Market size and forecast, by Prescription Type

9.4. Asia-Pacific

9.4.1. Key market trends, growth factors and opportunities

9.4.2. Market size and forecast, by Type

9.4.3. Market size and forecast, by Base

9.4.4. Market size and forecast, by Distribution Channel

9.4.5. Market size and forecast, by End User

9.4.6. Market size and forecast, by Prescription Type

9.4.7. Market size and forecast, by country

9.4.7.1. Japan

9.4.7.1.1. Market size and forecast, by Type

9.4.7.1.2. Market size and forecast, by Base

9.4.7.1.3. Market size and forecast, by Distribution Channel

9.4.7.1.4. Market size and forecast, by End User

9.4.7.1.5. Market size and forecast, by Prescription Type

9.4.7.2. China

9.4.7.2.1. Market size and forecast, by Type

9.4.7.2.2. Market size and forecast, by Base

9.4.7.2.3. Market size and forecast, by Distribution Channel

9.4.7.2.4. Market size and forecast, by End User

9.4.7.2.5. Market size and forecast, by Prescription Type

9.4.7.3. Australia

9.4.7.3.1. Market size and forecast, by Type

9.4.7.3.2. Market size and forecast, by Base

9.4.7.3.3. Market size and forecast, by Distribution Channel

9.4.7.3.4. Market size and forecast, by End User

9.4.7.3.5. Market size and forecast, by Prescription Type

9.4.7.4. India

9.4.7.4.1. Market size and forecast, by Type

9.4.7.4.2. Market size and forecast, by Base

9.4.7.4.3. Market size and forecast, by Distribution Channel

9.4.7.4.4. Market size and forecast, by End User

9.4.7.4.5. Market size and forecast, by Prescription Type

9.4.7.5. South Korea

9.4.7.5.1. Market size and forecast, by Type

9.4.7.5.2. Market size and forecast, by Base

9.4.7.5.3. Market size and forecast, by Distribution Channel

9.4.7.5.4. Market size and forecast, by End User

9.4.7.5.5. Market size and forecast, by Prescription Type

9.4.7.6. Rest of Asia-Pacific

9.4.7.6.1. Market size and forecast, by Type

9.4.7.6.2. Market size and forecast, by Base

9.4.7.6.3. Market size and forecast, by Distribution Channel

9.4.7.6.4. Market size and forecast, by End User

9.4.7.6.5. Market size and forecast, by Prescription Type

9.5. LAMEA

9.5.1. Key market trends, growth factors and opportunities

9.5.2. Market size and forecast, by Type

9.5.3. Market size and forecast, by Base

9.5.4. Market size and forecast, by Distribution Channel

9.5.5. Market size and forecast, by End User

9.5.6. Market size and forecast, by Prescription Type

9.5.7. Market size and forecast, by country

9.5.7.1. Brazil

9.5.7.1.1. Market size and forecast, by Type

9.5.7.1.2. Market size and forecast, by Base

9.5.7.1.3. Market size and forecast, by Distribution Channel

9.5.7.1.4. Market size and forecast, by End User

9.5.7.1.5. Market size and forecast, by Prescription Type

9.5.7.2. Saudi Arabia

9.5.7.2.1. Market size and forecast, by Type

9.5.7.2.2. Market size and forecast, by Base

9.5.7.2.3. Market size and forecast, by Distribution Channel

9.5.7.2.4. Market size and forecast, by End User

9.5.7.2.5. Market size and forecast, by Prescription Type

9.5.7.3. South Africa

9.5.7.3.1. Market size and forecast, by Type

9.5.7.3.2. Market size and forecast, by Base

9.5.7.3.3. Market size and forecast, by Distribution Channel

9.5.7.3.4. Market size and forecast, by End User

9.5.7.3.5. Market size and forecast, by Prescription Type

9.5.7.4. Rest of LAMEA

9.5.7.4.1. Market size and forecast, by Type

9.5.7.4.2. Market size and forecast, by Base

9.5.7.4.3. Market size and forecast, by Distribution Channel

9.5.7.4.4. Market size and forecast, by End User

9.5.7.4.5. Market size and forecast, by Prescription Type

10.1. Introduction

10.2. Top winning strategies

10.3. Product mapping of top 10 player

10.4. Competitive dashboard

10.5. Competitive heatmap

10.6. Top player positioning, 2022

11.1. Bayer AG

11.1.1. Company overview

11.1.2. Key executives

11.1.3. Company snapshot

11.1.4. Operating business segments

11.1.5. Product portfolio

11.1.6. Business performance

11.2. Bliss GVS Pharma Ltd

11.2.1. Company overview

11.2.2. Key executives

11.2.3. Company snapshot

11.2.4. Operating business segments

11.2.5. Product portfolio

11.2.6. Business performance

11.3. Viatris Inc.

11.3.1. Company overview

11.3.2. Key executives

11.3.3. Company snapshot

11.3.4. Operating business segments

11.3.5. Product portfolio

11.3.6. Business performance

11.4. Church & Dwight Co. Inc.

11.4.1. Company overview

11.4.2. Key executives

11.4.3. Company snapshot

11.4.4. Operating business segments

11.4.5. Product portfolio

11.4.6. Business performance

11.5. Glenmark Pharmaceuticals Limited

11.5.1. Company overview

11.5.2. Key executives

11.5.3. Company snapshot

11.5.4. Operating business segments

11.5.5. Product portfolio

11.5.6. Business performance

11.6. Intas Pharmaceuticals Ltd.

11.6.1. Company overview

11.6.2. Key executives

11.6.3. Company snapshot

11.6.4. Operating business segments

11.6.5. Product portfolio

11.7. Cadila Healthcare Ltd

11.7.1. Company overview

11.7.2. Key executives

11.7.3. Company snapshot

11.7.4. Operating business segments

11.7.5. Product portfolio

11.7.6. Business performance

11.7.7. Key strategic moves and developments

11.8. Novartis AG

11.8.1. Company overview

11.8.2. Key executives

11.8.3. Company snapshot

11.8.4. Operating business segments

11.8.5. Product portfolio

11.8.6. Business performance

11.9. Pfizer Inc.

11.9.1. Company overview

11.9.2. Key executives

11.9.3. Company snapshot

11.9.4. Operating business segments

11.9.5. Product portfolio

11.9.6. Business performance

11.10. Sanofi S.A.

11.10.1. Company overview

11.10.2. Key executives

11.10.3. Company snapshot

11.10.4. Operating business segments

11.10.5. Product portfolio

11.10.6. Business performanc

LIST OF TABLES

TABLE 01. GLOBAL PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 02. PHARMACEUTICAL SUPPOSITORIES MARKET FOR RECTAL SUPPOSITORIES, BY REGION, 2022-2032 ($MILLION)

TABLE 03. PHARMACEUTICAL SUPPOSITORIES MARKET FOR VAGINAL SUPPOSITORIES, BY REGION, 2022-2032 ($MILLION)

TABLE 04. PHARMACEUTICAL SUPPOSITORIES MARKET FOR URETHRAL SUPPOSITORIES, BY REGION, 2022-2032 ($MILLION)

TABLE 05. GLOBAL PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)

TABLE 06. PHARMACEUTICAL SUPPOSITORIES MARKET FOR FATTY BASES, BY REGION, 2022-2032 ($MILLION)

TABLE 07. PHARMACEUTICAL SUPPOSITORIES MARKET FOR WATER MISCIBLE BASE, BY REGION, 2022-2032 ($MILLION)

TABLE 08. GLOBAL WATER MISCIBLE BASE PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 09. PHARMACEUTICAL SUPPOSITORIES MARKET FOR EMULSIFYING BASES, BY REGION, 2022-2032 ($MILLION)

TABLE 10. GLOBAL EMULSIFYING BASES PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 11. GLOBAL PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 12. PHARMACEUTICAL SUPPOSITORIES MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)

TABLE 13. PHARMACEUTICAL SUPPOSITORIES MARKET FOR RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)

TABLE 14. PHARMACEUTICAL SUPPOSITORIES MARKET FOR ONLINE SALES, BY REGION, 2022-2032 ($MILLION)

TABLE 15. GLOBAL PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 16. PHARMACEUTICAL SUPPOSITORIES MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2022-2032 ($MILLION)

TABLE 17. PHARMACEUTICAL SUPPOSITORIES MARKET FOR HOME CARE, BY REGION, 2022-2032 ($MILLION)

TABLE 18. PHARMACEUTICAL SUPPOSITORIES MARKET FOR NURSING HOME, BY REGION, 2022-2032 ($MILLION)

TABLE 19. GLOBAL PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 20. PHARMACEUTICAL SUPPOSITORIES MARKET FOR OTC, BY REGION, 2022-2032 ($MILLION)

TABLE 21. PHARMACEUTICAL SUPPOSITORIES MARKET FOR PRESCRIBED SUPPOSITORIES, BY REGION, 2022-2032 ($MILLION)

TABLE 22. PHARMACEUTICAL SUPPOSITORIES MARKET, BY REGION, 2022-2032 ($MILLION)

TABLE 23. NORTH AMERICA PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 24. NORTH AMERICA PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)

TABLE 25. NORTH AMERICA PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 26. NORTH AMERICA PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 27. NORTH AMERICA PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 28. NORTH AMERICA PHARMACEUTICAL SUPPOSITORIES MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 29. U.S. PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 30. U.S. PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)

TABLE 31. U.S. PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 32. U.S. PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 33. U.S. PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 34. CANADA PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 35. CANADA PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)

TABLE 36. CANADA PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 37. CANADA PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 38. CANADA PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 39. MEXICO PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 40. MEXICO PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)

TABLE 41. MEXICO PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 42. MEXICO PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 43. MEXICO PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 44. EUROPE PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 45. EUROPE PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)

TABLE 46. EUROPE PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 47. EUROPE PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 48. EUROPE PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 49. EUROPE PHARMACEUTICAL SUPPOSITORIES MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 50. GERMANY PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 51. GERMANY PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)

TABLE 52. GERMANY PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 53. GERMANY PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 54. GERMANY PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 55. FRANCE PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 56. FRANCE PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)

TABLE 57. FRANCE PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 58. FRANCE PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 59. FRANCE PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 60. UK PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 61. UK PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)

TABLE 62. UK PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 63. UK PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 64. UK PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 65. ITALY PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 66. ITALY PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)

TABLE 67. ITALY PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 68. ITALY PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 69. ITALY PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 70. SPAIN PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 71. SPAIN PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)

TABLE 72. SPAIN PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 73. SPAIN PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 74. SPAIN PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 75. REST OF EUROPE PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 76. REST OF EUROPE PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)

TABLE 77. REST OF EUROPE PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 78. REST OF EUROPE PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 79. REST OF EUROPE PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 80. ASIA-PACIFIC PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 81. ASIA-PACIFIC PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)

TABLE 82. ASIA-PACIFIC PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 83. ASIA-PACIFIC PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 84. ASIA-PACIFIC PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 85. ASIA-PACIFIC PHARMACEUTICAL SUPPOSITORIES MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 86. JAPAN PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 87. JAPAN PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)

TABLE 88. JAPAN PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 89. JAPAN PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 90. JAPAN PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 91. CHINA PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 92. CHINA PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)

TABLE 93. CHINA PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 94. CHINA PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 95. CHINA PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 96. AUSTRALIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 97. AUSTRALIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)

TABLE 98. AUSTRALIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 99. AUSTRALIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 100. AUSTRALIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 101. INDIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 102. INDIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)

TABLE 103. INDIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 104. INDIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 105. INDIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 106. SOUTH KOREA PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 107. SOUTH KOREA PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)

TABLE 108. SOUTH KOREA PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 109. SOUTH KOREA PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 110. SOUTH KOREA PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 111. REST OF ASIA-PACIFIC PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 112. REST OF ASIA-PACIFIC PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)

TABLE 113. REST OF ASIA-PACIFIC PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 114. REST OF ASIA-PACIFIC PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 115. REST OF ASIA-PACIFIC PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 116. LAMEA PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 117. LAMEA PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)

TABLE 118. LAMEA PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 119. LAMEA PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 120. LAMEA PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 121. LAMEA PHARMACEUTICAL SUPPOSITORIES MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 122. BRAZIL PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 123. BRAZIL PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)

TABLE 124. BRAZIL PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 125. BRAZIL PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 126. BRAZIL PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 127. SAUDI ARABIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 128. SAUDI ARABIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)

TABLE 129. SAUDI ARABIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 130. SAUDI ARABIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 131. SAUDI ARABIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 132. SOUTH AFRICA PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 133. SOUTH AFRICA PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)

TABLE 134. SOUTH AFRICA PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 135. SOUTH AFRICA PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 136. SOUTH AFRICA PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 137. REST OF LAMEA PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 138. REST OF LAMEA PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)

TABLE 139. REST OF LAMEA PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 140. REST OF LAMEA PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 141. REST OF LAMEA PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 142. BAYER AG: KEY EXECUTIVES

TABLE 143. BAYER AG: COMPANY SNAPSHOT

TABLE 144. BAYER AG: PRODUCT SEGMENTS

TABLE 145. BAYER AG: PRODUCT PORTFOLIO

TABLE 146. BLISS GVS PHARMA LTD: KEY EXECUTIVES

TABLE 147. BLISS GVS PHARMA LTD: COMPANY SNAPSHOT

TABLE 148. BLISS GVS PHARMA LTD: PRODUCT SEGMENTS

TABLE 149. BLISS GVS PHARMA LTD: PRODUCT PORTFOLIO

TABLE 150. VIATRIS INC.: KEY EXECUTIVES

TABLE 151. VIATRIS INC.: COMPANY SNAPSHOT

TABLE 152. VIATRIS INC.: PRODUCT SEGMENTS

TABLE 153. VIATRIS INC.: PRODUCT PORTFOLIO

TABLE 154. CHURCH & DWIGHT CO. INC.: KEY EXECUTIVES

TABLE 155. CHURCH & DWIGHT CO. INC.: COMPANY SNAPSHOT

TABLE 156. CHURCH & DWIGHT CO. INC.: PRODUCT SEGMENTS

TABLE 157. CHURCH & DWIGHT CO. INC.: PRODUCT PORTFOLIO

TABLE 158. GLENMARK PHARMACEUTICALS LIMITED: KEY EXECUTIVES

TABLE 159. GLENMARK PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT

TABLE 160. GLENMARK PHARMACEUTICALS LIMITED: PRODUCT SEGMENTS

TABLE 161. GLENMARK PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO

TABLE 162. INTAS PHARMACEUTICALS LTD.: KEY EXECUTIVES

TABLE 163. INTAS PHARMACEUTICALS LTD.: COMPANY SNAPSHOT

TABLE 164. INTAS PHARMACEUTICALS LTD.: PRODUCT SEGMENTS

TABLE 165. INTAS PHARMACEUTICALS LTD.: PRODUCT PORTFOLIO

TABLE 166. CADILA HEALTHCARE LTD: KEY EXECUTIVES

TABLE 167. CADILA HEALTHCARE LTD: COMPANY SNAPSHOT

TABLE 168. CADILA HEALTHCARE LTD: PRODUCT SEGMENTS

TABLE 169. CADILA HEALTHCARE LTD: PRODUCT PORTFOLIO

TABLE 170. CADILA HEALTHCARE LTD: KEY STRATERGIES

TABLE 171. NOVARTIS AG: KEY EXECUTIVES

TABLE 172. NOVARTIS AG: COMPANY SNAPSHOT

TABLE 173. NOVARTIS AG: PRODUCT SEGMENTS

TABLE 174. NOVARTIS AG: PRODUCT PORTFOLIO

TABLE 175. PFIZER INC.: KEY EXECUTIVES

TABLE 176. PFIZER INC.: COMPANY SNAPSHOT

TABLE 177. PFIZER INC.: PRODUCT SEGMENTS

TABLE 178. PFIZER INC.: PRODUCT PORTFOLIO

TABLE 179. SANOFI S.A.: KEY EXECUTIVES

TABLE 180. SANOFI S.A.: COMPANY SNAPSHOT

TABLE 181. SANOFI S.A.: PRODUCT SEGMENTS

TABLE 182. SANOFI S.A.: PRODUCT PORTFOLIO LIST OF FIGURES

FIGURE 01. PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032

FIGURE 02. SEGMENTATION OF PHARMACEUTICAL SUPPOSITORIES MARKET,2022-2032

FIGURE 03. TOP IMPACTING FACTORS IN PHARMACEUTICAL SUPPOSITORIES MARKET (2022 TO 2032)

FIGURE 04. TOP INVESTMENT POCKETS IN PHARMACEUTICAL SUPPOSITORIES MARKET (2023-2032)

FIGURE 05. HIGH BARGAINING POWER OF SUPPLIERS

FIGURE 06. MODERATE THREAT OF NEW ENTRANTS

FIGURE 07. MODERATE THREAT OF SUBSTITUTES

FIGURE 08. MODERATE INTENSITY OF RIVALRY

FIGURE 09. MODERATE BARGAINING POWER OF BUYERS

FIGURE 10. GLOBAL PHARMACEUTICAL SUPPOSITORIES MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 11. PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022 AND 2032(%)

FIGURE 12. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUPPOSITORIES MARKET FOR RECTAL SUPPOSITORIES, BY COUNTRY 2022 AND 2032(%)

FIGURE 13. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUPPOSITORIES MARKET FOR VAGINAL SUPPOSITORIES, BY COUNTRY 2022 AND 2032(%)

FIGURE 14. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUPPOSITORIES MARKET FOR URETHRAL SUPPOSITORIES, BY COUNTRY 2022 AND 2032(%)

FIGURE 15. PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022 AND 2032(%)

FIGURE 16. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUPPOSITORIES MARKET FOR FATTY BASES, BY COUNTRY 2022 AND 2032(%)

FIGURE 17. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUPPOSITORIES MARKET FOR WATER MISCIBLE BASE, BY COUNTRY 2022 AND 2032(%)

FIGURE 18. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUPPOSITORIES MARKET FOR EMULSIFYING BASES, BY COUNTRY 2022 AND 2032(%)

FIGURE 19. PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022 AND 2032(%)

FIGURE 20. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUPPOSITORIES MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)

FIGURE 21. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUPPOSITORIES MARKET FOR RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)

FIGURE 22. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUPPOSITORIES MARKET FOR ONLINE SALES, BY COUNTRY 2022 AND 2032(%)

FIGURE 23. PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022 AND 2032(%)

FIGURE 24. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUPPOSITORIES MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY 2022 AND 2032(%)

FIGURE 25. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUPPOSITORIES MARKET FOR HOME CARE, BY COUNTRY 2022 AND 2032(%)

FIGURE 26. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUPPOSITORIES MARKET FOR NURSING HOME, BY COUNTRY 2022 AND 2032(%)

FIGURE 27. PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022 AND 2032(%)

FIGURE 28. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUPPOSITORIES MARKET FOR OTC, BY COUNTRY 2022 AND 2032(%)

FIGURE 29. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUPPOSITORIES MARKET FOR PRESCRIBED SUPPOSITORIES, BY COUNTRY 2022 AND 2032(%)

FIGURE 30. PHARMACEUTICAL SUPPOSITORIES MARKET BY REGION, 2022 AND 2032(%)

FIGURE 31. U.S. PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)

FIGURE 32. CANADA PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)

FIGURE 33. MEXICO PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)

FIGURE 34. GERMANY PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)

FIGURE 35. FRANCE PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)

FIGURE 36. UK PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)

FIGURE 37. ITALY PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)

FIGURE 38. SPAIN PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)

FIGURE 39. REST OF EUROPE PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)

FIGURE 40. JAPAN PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)

FIGURE 41. CHINA PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)

FIGURE 42. AUSTRALIA PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)

FIGURE 43. INDIA PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)

FIGURE 44. SOUTH KOREA PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)

FIGURE 45. REST OF ASIA-PACIFIC PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)

FIGURE 46. BRAZIL PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)

FIGURE 47. SAUDI ARABIA PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)

FIGURE 48. SOUTH AFRICA PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)

FIGURE 49. REST OF LAMEA PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)

FIGURE 50. TOP WINNING STRATEGIES, BY YEAR (2020-2023)

FIGURE 51. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)

FIGURE 52. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)

FIGURE 53. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 54. COMPETITIVE DASHBOARD

FIGURE 55. COMPETITIVE HEATMAP: PHARMACEUTICAL SUPPOSITORIES MARKET

FIGURE 56. TOP PLAYER POSITIONING, 2022

FIGURE 57. BAYER AG: NET SALES, 2020-2022 ($MILLION)

FIGURE 58. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 59. BAYER AG: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 60. BLISS GVS PHARMA LTD: NET REVENUE, 2021-2023 ($MILLION)

FIGURE 61. VIATRIS INC.: NET SALES, 2020-2022 ($MILLION)

FIGURE 62. VIATRIS INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 63. CHURCH & DWIGHT CO. INC.: NET SALES, 2020-2022 ($MILLION)

FIGURE 64. CHURCH & DWIGHT CO. INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 65. GLENMARK PHARMACEUTICALS LIMITED: NET REVENUE, 2019-2021 ($MILLION)

FIGURE 66. GLENMARK PHARMACEUTICALS LIMITED: REVENUE SHARE BY REGION, 2021 (%)

FIGURE 67. CADILA HEALTHCARE LTD: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 68. CADILA HEALTHCARE LTD: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 69. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)

FIGURE 70. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 71. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 72. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 73. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 74. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 75. SANOFI S.A.: NET SALES, 2020-2022 ($MILLION)

FIGURE 76. SANOFI S.A.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 77. SANOFI S.A.: REVENUE SHARE BY REGION, 2022 (%